期刊
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
卷 32, 期 3, 页码 778-U543出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/ATVBAHA.111.241067
关键词
antiplatelet drugs; collagen; monoclonal antibodies; platelets; glycoprotein VI
资金
- Institut National de la Sante et de la Recherche Medicale
- University of Paris Denis Diderot
- Fondation de France [2007001960]
- Institut de l'Atherothrombose
- Federation Francaise de Cardiologie-Societe Francaise de Cardiologie
- Departement a la Recherche Clinique et au Developpement de l'Assistance Publique-Hopitaux de Paris
Objective-The immune receptor homologue glycoprotein VI (GPVI)/FcR receptor gamma chain complex is primarily responsible for platelet activation by collagen. There is growing evidence that optimal binding of GPVI to collagen depends on the assembly of GPVI dimers. The valence of GPVI on resting platelets needs to be clearly established because platelet avidity for collagen would be greater if GPVI is constitutively expressed as a dimer than as a monomer. Methods and Results-Using a monoclonal antibody (9E18) that preferentially binds to GPVI dimers, we found that GPVI was maintained in a monomeric form on human resting platelets under the control of intraplatelet cAMP concentration. Activation by soluble agonists or von Willebrand factor induced a shift toward GPVI dimerization related to increased platelet adhesion to collagen. A correlation between platelet binding of 9E18 and P-selectin exposure was observed in patients experiencing coronary artery disease, and antagonists of the ADP receptor P2Y(12) limited ADP-induced GPVI dimerization. Conclusion-The rapid assembly of highly competent dimers of GPVI at sites of vascular lesion represents an important step in the sequence of events leading to platelet activation by collagen. GPVI dimers could represent a new marker to analyze platelet reactivity. (Arterioscler Thromb Vasc Biol. 2012; 32:778-785.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据